Behavior analysis in the era of medicalization: the state of the science and recommendations for practitioners.

Wyatt (2009) wrote a how-to guide for BCBAs who face parents asking, "Why not just try medication?"

The paper lists weak spots in drug studies—short follow-ups, no behavior data, group averages that hide individual loss of skills.

It gives talking points you can use in team meetings or at the kitchen table to keep the conversation on behavior plans.

The guide shows that most medication studies stop tracking kids after a few weeks, while ABA data can run for months or years.

By spotlighting those gaps, you can calmly explain why behavioral methods stay in the plan first.

Capuano et al. (2021) extends the same idea to pseudoscience. Where Joseph taught you to push back against meds, Capuano hands you a polite script for refusing fad diets or bleach protocols while keeping parents on your side.

Walton (2016) takes the fight outward. After you win the kitchen-table debate with Joseph’s flaws list, M shows how to wrap ABA in warmer words so schools and funders say yes.

de la Cruz et al. (2025) moves the talk to the statehouse. The 2009 paper arms one BCBA; the 2025 special issue turns those talking points into lobby days that secure licensure and insurance dollars.

You now have a three-step ladder: use Joseph’s drug-study flaws to keep behavior plans in place, add Capuano’s scripts when parents chase fads, and point to de la Cruz when you need policy backup. One short paper from 2009 still anchors your clinical story, and later work keeps expanding where that story can travel.